1 ntified as the tumor product responsible for humoral hypercalcemia of malignancy.

2 ly discovered as a tumor product that causes humoral hypercalcemia of malignancy.

3 r its activity in a syngeneic tumor model of humoral hypercalcemia of malignancy.

4 protein (PTHrP) is the agent responsible for humoral hypercalcemia of malignancy.

5 combined immune deficiency mice and produced humoral hypercalcemia of malignancy.

6 signaling as a novel therapeutic approach in humoral hypercalcemia of malignancy and possibly multipl

7                                              Humoral hypercalcemia of malignancy (HHM) is caused by t

8 ne disease associated with breast cancer and humoral hypercalcemia of malignancy (HHM) that occurs wi

9   Approximately 80% of ATLL patients develop humoral hypercalcemia of malignancy (HHM), a life-threat

10 s recognized as the major causative agent of humoral hypercalcemia of malignancy (HHM).

11 opic virus type-1 (HTLV-1) infection develop humoral hypercalcemia of malignancy (HHM).

12                                In a model of humoral hypercalcemia of malignancy in which PTHrP secre

13            The potent effects of OPG in this humoral hypercalcemia of malignancy model suggest a pote

14                                              Humoral hypercalcemia of malignancy results from the eff